Non Invasive Measurements of Intracranial Pressure in Patients With Malignant Glioma

NCT02520492 | Completed

• 1 other identifier: 2014-A01568-39
• Study Type: interventional
• Target: 40
• Locations: 1 country
• Sites: 1

Brief Summary

In patients at risk of increased intracranial pressure (ICP), ICP measurements require invasive transducers, usually with insertion of a catheter into the cranium, or through a spinal tap. These invasive modalities involve risks and pain and they can be done only in specialized care units, with a high associated cost. A novel method for detecting changes in ICP has developed recently. The auditory hair cells emit sounds and electric signals in response to sound, which can be easily detected and measured non-invasively with the help of a microphone probe placed in the external ear canal or regular electrodes. Indeed, the cochlear aqueduct connects the cerebrospinal fluid (CSF) spaces to the inner ear in such a way that ICP and inner-ear fluid pressure equalize within seconds. A symptom of intracranial pressure (ICP) was observed in glioma patient due to a combination of causes: the inflammatory reaction around the tumor, the mass effect of the tumor, secondary vascular changes, a change in the flow of CSF. The evaluation of intracranial hypertension by increased ICP (invasive) is not used in the monitoring of intracranial tumors. It is then detected by using routine clinical signs, in combination with a standard imaging method (MRI), but still subjective. The measurement of noninvasive ICP could allow earlier detection of relapse, and evaluate whether the increase in ICP precedes tumor clinical worsening and / or imaging.

Conditions

Glioma

Keywords

intracranial pressure

Outcome Measures

Primary Outcomes (1)

• Presence of an ICP variation or increase when physician has diagnosed a clinical or morphological aggravation of the tumor with standard diagnose methods (composite outcome measure)

  Presence of an ICP variation or increase when physician has diagnosed a clinical or morphological aggravation of the tumor with standard diagnose methods (composite outcome measure ) : clinical signs, MRI and response assessment in neuro-oncology criteria (RANO) .

  from baseline to 1 year

Secondary Outcomes (3)

• evolution of ICP before and after the progression of the relapse tumor according to imaging (RMI)

  from baseline to 1 year

• evolution of ICP before and after the progression of the relapse tumor according to clinical sign

  from baseline to 1 year

• Evaluate efficiency of the measurement device of ICP changes on repetitive measurement as evaluated by composite outcome measure : clinical signs, MRI and RANO criteria

  from baseline to 1 year

Study Arms (1)

noninvasive method of ICP measurements

EXPERIMENTAL

Patients will receive a noninvasive measurement of ICP variations during each of their follow up consultation. These measurements will last until 30 minutes for the first consultation (parameters to determine) and 10 minutes for the others. A postural test will be performed during the ICP measurements when the patient condition will make it possible to do. Measurements will be performed by a device with noninvasive acoustic probes placed in the ear, and in case of electrophysiological test, regular electrodes on the brow.

Device: noninvasive method of ICP measurements (Elios)

Interventions

noninvasive method of ICP measurements (Elios) DEVICE

Also known as: Elios device from ECHODIA company

noninvasive method of ICP measurements

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients with malignant glioma who underwent a biopsy or a partial surgery of this tumor and a radiotherapy and/or chemotherapy treatment.
• Valid tympanometry test at least for one ear
• Between 18 and 65 years of age
• Cochlear response useful at least for an ear which has validate the tympanometry test
• Written informed consent reviewed and signed by patient
• Affiliation to a social security scheme

You may not qualify if:

• Patients who underwent a complete resection of their malignant glioma
• Invalid tympanometry test for the both ears
• Collect of cochlear responses impossible for the ear or both ear which validate the tympanometry test
• Patient refusal after enlightened information

Sponsors & Collaborators

• Centre Jean Perrin: lead
• Laboratoire de Biophysique Neurosensorielle - UMR INSERM 1107 (Pr Paul AVAN): collaborator

Study Sites (1)

Centre Jean Perrin

Clermont-Ferrand, 63011, France

Location

Related Publications (1)

• Casile M, Thivat E, Giraudet F, Ginzac A, Molnar I, Biau J, Brehant J, Lourenco B, Avan P, Durando X. Non-invasive intracranial pressure monitoring for high-grade gliomas patients treated with radiotherapy: results of the GMaPIC trial. Front Oncol. 2024 Jun 11;14:1302977. doi: 10.3389/fonc.2024.1302977. eCollection 2024.

  PMID: 38919520 DERIVED

MeSH Terms

Conditions

Glioma

Condition Hierarchy (Ancestors)

Neoplasms, Neuroepithelial; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Glandular and Epithelial; Neoplasms, Nerve Tissue

Study Officials

• Xavier DURANDO, MD

  Centre Jean Perrin

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: DIAGNOSTIC
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 24, 2015
• First Posted: August 13, 2015
• Study Start: April 3, 2015
• Primary Completion: January 15, 2020
• Study Completion: January 15, 2020
• Last Updated: January 31, 2020

Record last verified: 2020-01

Locations

FR (1)